Genmab — November 2020
-
Aktierne stiger vel fordi risikoen for en „Blue Wave“ er næsten nul nu, i og med at senatet ser ud til at forblive med republikansk flertal
-
Tror mere det er udsigten til spændende præsentationer med både PD-L1/4-1BB og epcoritamab samt det faktum, at DuoBody platformen begynder at ligne den førende platform til BsAbs. Og da retningen tydelig vis er mod disse, så er det jo en gave at sidde med denne platform
-
Enig Sukkeralf. Min kommentar var relateret til markedet...
-
ja, og på trods af voldgiftsagen...
-
"So for the Fas-4-1BB, the Fas has to globalize, the 4-1BB. PD-L1, 4-1BB is a different concept. It’s not only the localization based on the presence of PD-L1, but you have, it was signaling the inhibition of the PD-1, PD-L1 axis plus the 4-1BB in the context of the cell-cell synapsis, that acts like as a zipper. So I think that this biologically is different than the concept of the Fas-4-1BB."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind